source
- AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trialAriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
- FDA approves Roche's new breast cancer drug, poised to become its top-selling productThe U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…